The Cooper Companies, Inc. (NASDAQ:COO) Shares Sold by Creative Planning

Creative Planning cut its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 2.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,661 shares of the medical device company’s stock after selling 234 shares during the quarter. Creative Planning’s holdings in Cooper Companies were worth $931,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in COO. Benjamin F. Edwards & Company Inc. increased its position in Cooper Companies by 248.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock valued at $25,000 after acquiring an additional 174 shares during the period. Innealta Capital LLC purchased a new stake in shares of Cooper Companies during the second quarter worth approximately $25,000. Covestor Ltd raised its stake in shares of Cooper Companies by 305.9% during the first quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock worth $28,000 after purchasing an additional 208 shares during the last quarter. Crewe Advisors LLC lifted its holdings in shares of Cooper Companies by 286.4% during the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after purchasing an additional 252 shares during the period. Finally, Tortoise Investment Management LLC grew its position in Cooper Companies by 75.4% in the 2nd quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock valued at $34,000 after buying an additional 169 shares during the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Piper Sandler raised their target price on shares of Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Morgan Stanley lifted their price objective on Cooper Companies from $95.00 to $104.00 and gave the company an “equal weight” rating in a report on Tuesday, September 10th. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Wells Fargo & Company lifted their price target on Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. Finally, Jefferies Financial Group upgraded Cooper Companies from a “hold” rating to a “buy” rating and increased their price objective for the stock from $107.00 to $115.00 in a research report on Tuesday, July 16th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $115.00.

Cooper Companies Trading Down 0.5 %

Shares of COO stock opened at $106.30 on Friday. The stock has a market cap of $21.17 billion, a P/E ratio of 62.53, a P/E/G ratio of 2.63 and a beta of 0.98. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The Cooper Companies, Inc. has a fifty-two week low of $75.93 and a fifty-two week high of $112.38. The business has a fifty day simple moving average of $102.46 and a 200-day simple moving average of $96.16.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $997.30 million. During the same period last year, the firm posted $0.84 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, analysts forecast that The Cooper Companies, Inc. will post 3.65 earnings per share for the current fiscal year.

Insider Activity at Cooper Companies

In other Cooper Companies news, CEO Albert G. White III sold 114,992 shares of the firm’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the completion of the transaction, the chief executive officer now owns 165,273 shares of the company’s stock, valued at approximately $18,267,624.69. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CAO Agostino Ricupati sold 1,601 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total transaction of $172,956.03. Following the sale, the chief accounting officer now owns 4,818 shares in the company, valued at approximately $520,488.54. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Albert G. White III sold 114,992 shares of Cooper Companies stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the completion of the sale, the chief executive officer now directly owns 165,273 shares of the company’s stock, valued at $18,267,624.69. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 256,373 shares of company stock valued at $27,637,427. 2.00% of the stock is owned by corporate insiders.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.